CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Menu
Begin main content
Home Search
Result Type
Evidence Bundles
Product Line
Body Systems
Disease and Conditions
Target Population
Technologies, Therapies and Systems
Testing and Diagnostics
Publication Date
Clear all filters

Reports

We found 6218 result(s)

budesonide (Jorveza )

Last Updated: November 20, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: budesonide
Indications: Indicated for the induction and maintenance of clinico-pathological remission in adults with eosinophilic esophagitis (EoE).

  • Brand Name: Jorveza
  • Manufacturer: AVIR Pharma Inc
  • Project Number: SR0666-000
  • Project Status: Active
  • Submission Type: Initial
Details

ranolazine (TBC)

Last Updated: November 18, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: ranolazine
Indications: Indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies (such as beta-blockers and/or calcium antagonists). Ranolazine may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers

  • Brand Name: TBC
  • Manufacturer: KYE Pharmaceuticals Inc.
  • Project Number: SR0655-000
  • Project Status: Active
  • Submission Type: Initial
Details

amifampridine (Ruzurgi)

Last Updated: November 23, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: amifampridine
Indications: Indicated for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 years of age and older.

  • Brand Name: Ruzurgi
  • Manufacturer: Médunik Canada Inc.
  • Project Number: SR0660-000
  • Project Status: Active
  • Submission Type: Initial
Details

etonogestrel (Nexplanon)

Last Updated: November 20, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: etonogestrel
Indications: Indicated for the prevention of pregnancy for up to 3 years

  • Brand Name: Nexplanon
  • Manufacturer: Merck Canada Inc.
  • Project Number: SR0648-000
  • Project Status: Active
  • Submission Type: Initial
Details

fremanezumab (Ajovy)

Last Updated: November 19, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: fremanezumab
Indications: ​Indicated for the prevention of migraine in adults who have at least 4 migraine days per month.

  • Brand Name: Ajovy
  • Manufacturer: Teva Canada Innovation
  • Project Number: SR0641-000
  • Project Status: Active
  • Submission Type: Initial
Details

Nivolumab-Ipilimumab (Opdivo-Yervoy)

Last Updated: November 23, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: nivolumab-ipilimumab
Indications: ​OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.

  • Brand Name: Opdivo-Yervoy
  • Manufacturer: Bristol-Myers Squibb
  • Project Number: PC0229-000
  • Project Status: Active
  • Submission Type: Initial
Details

dinutuximab (Unituxin)

Last Updated: November 23, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: dinutuximab
Indications: For the treatment of pediatric patients with relapsed/refractory high-risk neuroblastoma in combination with irinotecan, temozolomide, and granulocyte macrophage colony-stimulating factor.

  • Brand Name: Unituxin
  • Manufacturer: United Therapeutics Corp.
  • Project Number: PC0222-000
  • Project Status: Received
  • Submission Type: Initial
Details

chlormethine hydrochloride (Ledaga)

Last Updated: November 23, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: chlormethine hydrochloride
Indications: For the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients.

  • Brand Name: Ledaga
  • Manufacturer: Recordati Rare Diseases Canada Inc.
  • Project Number: PC0242-000
  • Project Status: Pending
  • Submission Type: Initial
Details

COVID-19 Update

Last Updated: November 23, 2020
Result type: Reports
Product Line: New at CADTH

CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time. Our COVID-19 evidence portal contains the latest COVID-19 information from CADTH and other respected organizations. Content is updated daily to reflect the rapidly changing and growing state of the international scientific evidence...